vs
ON24 INC.（ONTF）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
ON24 INC.的季度营收约是REGENXBIO Inc.的1.1倍（$34.6M vs $30.3M），ON24 INC.净利率更高（-18.8% vs -221.3%，领先202.6%），REGENXBIO Inc.同比增速更快（43.0% vs -5.6%），ON24 INC.自由现金流更多（$-2.2M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs -4.2%）
ON24 INC.是一家总部位于美国旧金山的企业，为B2B企业的营销与销售团队提供基于云的SaaS服务，开发并提供网络研讨会、虚拟会议、内容中心与着陆页应用，2023年其服务范围已扩展至生成式AI领域。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
ONTF vs RGNX — 直观对比
营收规模更大
ONTF
是对方的1.1倍
$30.3M
营收增速更快
RGNX
高出48.6%
-5.6%
净利率更高
ONTF
高出202.6%
-221.3%
自由现金流更多
ONTF
多$50.6M
$-52.8M
两年增速更快
RGNX
近两年复合增速
-4.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $34.6M | $30.3M |
| 净利润 | $-6.5M | $-67.1M |
| 毛利率 | 74.9% | — |
| 营业利润率 | -23.5% | -190.0% |
| 净利率 | -18.8% | -221.3% |
| 营收同比 | -5.6% | 43.0% |
| 净利润同比 | 26.8% | -31.2% |
| 每股收益（稀释后） | $-0.15 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ONTFRGNX
| Q4 25 | $34.6M | $30.3M | ||
| Q3 25 | $34.6M | $29.7M | ||
| Q2 25 | $35.3M | $21.4M | ||
| Q1 25 | $34.7M | $89.0M | ||
| Q4 24 | $36.7M | $21.2M | ||
| Q3 24 | $36.3M | $24.2M | ||
| Q2 24 | $37.3M | $22.3M | ||
| Q1 24 | $37.7M | $15.6M |
净利润ONTFRGNX
| Q4 25 | $-6.5M | $-67.1M | ||
| Q3 25 | $-6.4M | $-61.9M | ||
| Q2 25 | $-7.3M | $-70.9M | ||
| Q1 25 | $-8.7M | $6.1M | ||
| Q4 24 | $-8.9M | $-51.2M | ||
| Q3 24 | $-11.4M | $-59.6M | ||
| Q2 24 | $-11.2M | $-53.0M | ||
| Q1 24 | $-10.7M | $-63.3M |
毛利率ONTFRGNX
| Q4 25 | 74.9% | — | ||
| Q3 25 | 74.7% | — | ||
| Q2 25 | 75.1% | — | ||
| Q1 25 | 73.8% | — | ||
| Q4 24 | 74.5% | 70.2% | ||
| Q3 24 | 74.3% | 48.8% | ||
| Q2 24 | 74.5% | 52.5% | ||
| Q1 24 | 74.1% | 72.6% |
营业利润率ONTFRGNX
| Q4 25 | -23.5% | -190.0% | ||
| Q3 25 | -23.1% | -176.3% | ||
| Q2 25 | -26.0% | -296.3% | ||
| Q1 25 | -30.1% | 13.6% | ||
| Q4 24 | -32.1% | -242.1% | ||
| Q3 24 | -36.7% | -256.6% | ||
| Q2 24 | -35.0% | -251.3% | ||
| Q1 24 | -33.1% | -408.8% |
净利率ONTFRGNX
| Q4 25 | -18.8% | -221.3% | ||
| Q3 25 | -18.4% | -208.3% | ||
| Q2 25 | -20.6% | -331.8% | ||
| Q1 25 | -25.1% | 6.8% | ||
| Q4 24 | -24.2% | -241.3% | ||
| Q3 24 | -31.4% | -246.3% | ||
| Q2 24 | -29.9% | -237.7% | ||
| Q1 24 | -28.4% | -405.4% |
每股收益（稀释后）ONTFRGNX
| Q4 25 | $-0.15 | $-1.30 | ||
| Q3 25 | $-0.15 | $-1.20 | ||
| Q2 25 | $-0.17 | $-1.38 | ||
| Q1 25 | $-0.21 | $0.12 | ||
| Q4 24 | $-0.21 | $-0.99 | ||
| Q3 24 | $-0.27 | $-1.17 | ||
| Q2 24 | $-0.27 | $-1.05 | ||
| Q1 24 | $-0.26 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $37.0M | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $139.4M | $102.7M |
| 总资产 | $228.4M | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ONTFRGNX
| Q4 25 | $37.0M | $230.1M | ||
| Q3 25 | $47.2M | $274.2M | ||
| Q2 25 | $37.7M | $323.3M | ||
| Q1 25 | $26.8M | $267.9M | ||
| Q4 24 | $14.9M | $234.7M | ||
| Q3 24 | $11.0M | $255.5M | ||
| Q2 24 | $15.5M | $290.4M | ||
| Q1 24 | $18.3M | $338.7M |
股东权益ONTFRGNX
| Q4 25 | $139.4M | $102.7M | ||
| Q3 25 | $144.3M | $161.5M | ||
| Q2 25 | $150.0M | $213.7M | ||
| Q1 25 | $153.7M | $274.2M | ||
| Q4 24 | $159.4M | $259.7M | ||
| Q3 24 | $164.9M | $301.4M | ||
| Q2 24 | $170.8M | $348.3M | ||
| Q1 24 | $174.4M | $390.7M |
总资产ONTFRGNX
| Q4 25 | $228.4M | $453.0M | ||
| Q3 25 | $224.8M | $525.2M | ||
| Q2 25 | $235.1M | $581.0M | ||
| Q1 25 | $245.8M | $490.9M | ||
| Q4 24 | $251.0M | $466.0M | ||
| Q3 24 | $250.9M | $519.1M | ||
| Q2 24 | $259.0M | $569.4M | ||
| Q1 24 | $269.2M | $629.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-1.1M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $-2.2M | $-52.8M |
| 自由现金流率自由现金流/营收 | -6.4% | -174.0% |
| 资本支出强度资本支出/营收 | 3.3% | 1.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $4.0M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流ONTFRGNX
| Q4 25 | $-1.1M | $-52.3M | ||
| Q3 25 | $2.5M | $-56.0M | ||
| Q2 25 | $2.6M | $-49.3M | ||
| Q1 25 | $3.4M | $33.6M | ||
| Q4 24 | $985.0K | $-31.6M | ||
| Q3 24 | $295.0K | $-40.5M | ||
| Q2 24 | $1.4M | $-45.5M | ||
| Q1 24 | $2.1M | $-55.5M |
自由现金流ONTFRGNX
| Q4 25 | $-2.2M | $-52.8M | ||
| Q3 25 | $2.2M | $-56.5M | ||
| Q2 25 | $2.1M | $-49.7M | ||
| Q1 25 | $1.9M | $32.6M | ||
| Q4 24 | $424.0K | $-32.7M | ||
| Q3 24 | $143.0K | $-40.9M | ||
| Q2 24 | $898.0K | $-46.0M | ||
| Q1 24 | $1.1M | $-56.0M |
自由现金流率ONTFRGNX
| Q4 25 | -6.4% | -174.0% | ||
| Q3 25 | 6.2% | -189.9% | ||
| Q2 25 | 5.9% | -232.8% | ||
| Q1 25 | 5.6% | 36.6% | ||
| Q4 24 | 1.2% | -154.2% | ||
| Q3 24 | 0.4% | -168.9% | ||
| Q2 24 | 2.4% | -206.2% | ||
| Q1 24 | 2.9% | -358.5% |
资本支出强度ONTFRGNX
| Q4 25 | 3.3% | 1.7% | ||
| Q3 25 | 1.1% | 1.7% | ||
| Q2 25 | 1.4% | 1.8% | ||
| Q1 25 | 4.2% | 1.2% | ||
| Q4 24 | 1.5% | 5.1% | ||
| Q3 24 | 0.4% | 1.3% | ||
| Q2 24 | 1.3% | 2.1% | ||
| Q1 24 | 2.8% | 3.6% |
现金转化率ONTFRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 5.53× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ONTF
暂无分部数据
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
